Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s66, 2022. DOI: 10.25251/skin.6.supp.66. Disponível em: https://skin.dermsquared.com/skin/article/view/1821. Acesso em: 9 mar. 2026.